Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for OYSTER PT PHARM (OYST : NSDQ)
 
 • Company Description   
Oyster Point Pharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company's lead product candidate, OC-01, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Oyster Point Pharma Inc. is based in Princeton, New Jersey.

Number of Employees: 303

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.99 Daily Weekly Monthly
20 Day Moving Average: 121,670 shares
Shares Outstanding: 26.67 (millions)
Market Capitalization: $106.41 (millions)
Beta: 0.99
52 Week High: $21.01
52 Week Low: $3.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -42.92% -37.50%
12 Week -63.56% -59.05%
Year To Date -78.15% -73.31%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
202 CARNEGIE CENTER SUITE 109
-
PRINCETON,NJ 08540
USA
ph: 609-382-9032
fax: -
investors@oysterpointrx.com http://www.oysterpointrx.com
 
 • General Corporate Information   
Officers
Jeffrey Nau - Chief Executive Officer; President and Director
Donald Santel - Chair of the Board
Daniel Lochner - Chief Financial Officer
George Eliades - Director
Michael Atieh - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 69242L106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 26.67
Most Recent Split Date: (:1)
Beta: 0.99
Market Capitalization: $106.41 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.59 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-6.18 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.90
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -146.58%
vs. Previous Quarter: -11.80%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -59.01%
ROE
03/31/22 - -116.58
12/31/21 - -71.97
09/30/21 - -50.00
ROA
03/31/22 - -68.61
12/31/21 - -52.71
09/30/21 - -43.74
Current Ratio
03/31/22 - 7.27
12/31/21 - 7.47
09/30/21 - 12.51
Quick Ratio
03/31/22 - 7.09
12/31/21 - 7.26
09/30/21 - 12.51
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -475.87
12/31/21 - -410.20
09/30/21 - -450.46
Book Value
03/31/22 - 2.10
12/31/21 - 3.80
09/30/21 - 5.26
Inventory Turnover
03/31/22 - 0.73
12/31/21 - 1.00
09/30/21 - -
Debt-to-Equity
03/31/22 - 1.62
12/31/21 - 0.90
09/30/21 - 0.30
Debt-to-Capital
03/31/22 - 61.81
12/31/21 - 47.43
09/30/21 - 23.36
 

Powered by Zacks Investment Research ©